A Lack of Premature Termination Codon Read-through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays

Overview

Journal PLoS Biol

Specialty Biology

Date 2013 Jul 5

PMID 23824517

Citations 67

Authors

Stuart P McElroy

Toshifumi Nomura

Leah S Torrie

Emma Warbrick

Ulrike Gartner

Gavin Wood

W H Irwin McLean

Affiliations

Soon will be listed here.

Abstract

The drug molecule PTC124 (Ataluren) has been described as a read-through agent, capable of suppressing premature termination codons (PTCs) and restoring functional protein production from genes disrupted by nonsense mutations. Following the discovery of PTC124 there was some controversy regarding its mechanism of action with two reports attributing its activity to an off-target effect on the Firefly luciferase (FLuc) reporter used in the development of the molecule. Despite questions remaining as to its mechanism of action, development of PTC124 continued into the clinic and it is being actively pursued as a potential nonsense mutation therapy. To thoroughly test the ability of PTC124 to read through nonsense mutations, we conducted a detailed assessment comparing the efficacy of PTC124 with the classical aminoglycoside antibiotic read-through agent geneticin (G418) across a diverse range of in vitro reporter assays. We can confirm the off-target FLuc activity of PTC124 but found that, while G418 exhibits varying activity in every read-through assay, there is no evidence of activity for PTC124.

Citing Articles

Cystic Fibrosis: A Journey through Time and Hope.

Trouve P, Saint Pierre A, Ferec C Int J Mol Sci. 2024; 25(17).

PMID: 39273547 PMC: 11394767. DOI: 10.3390/ijms25179599.

Therapeutic targeting of RNA for neurological and neuromuscular disease.

Bubenik J, Scotti M, Swanson M Genes Dev. 2024; 38(15-16):698-717.

PMID: 39142832 PMC: 11444190. DOI: 10.1101/gad.351612.124.

Therapeutic approaches for Duchenne muscular dystrophy.

Roberts T, Wood M, Davies K Nat Rev Drug Discov. 2023; 22(11):917-934.

PMID: 37652974 DOI: 10.1038/s41573-023-00775-6.

Duchenne muscular dystrophy: disease mechanism and therapeutic strategies.

Bez Batti Angulski A, Hosny N, Cohen H, Martin A, Hahn D, Bauer J Front Physiol. 2023; 14:1183101.

PMID: 37435300 PMC: 10330733. DOI: 10.3389/fphys.2023.1183101.

Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development.

Li S, Li J, Shi W, Nie Z, Zhang S, Ma F Biomolecules. 2023; 13(6).

PMID: 37371567 PMC: 10296333. DOI: 10.3390/biom13060988.

References

Dranchak P, Di Pietro E, Snowden A, Oesch N, Braverman N, Steinberg S . Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations. J Cell Biochem. 2011; 112(5):1250-8. PMC: 3136445. DOI: 10.1002/jcb.22979. View

Manuvakhova M, Keeling K, Bedwell D . Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA. 2000; 6(7):1044-55. PMC: 1369979. DOI: 10.1017/s1355838200000716. View

Wilschanski M, Miller L, Shoseyov D, Blau H, Rivlin J, Aviram M . Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J. 2011; 38(1):59-69. DOI: 10.1183/09031936.00120910. View

Brumm H, Muhlhaus J, Bolze F, Scherag S, Hinney A, Hebebrand J . Rescue of melanocortin 4 receptor (MC4R) nonsense mutations by aminoglycoside-mediated read-through. Obesity (Silver Spring). 2011; 20(5):1074-81. DOI: 10.1038/oby.2011.202. View

Wang B, Yang Z, Brisson B, Feng H, Zhang Z, Welch E . Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. J Appl Physiol (1985). 2010; 109(3):901-5. PMC: 3774516. DOI: 10.1152/japplphysiol.01366.2009. View

Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M . Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008; 372(9640):719-27. DOI: 10.1016/S0140-6736(08)61168-X. View

Du M, Liu X, Welch E, Hirawat S, Peltz S, Bedwell D . PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A. 2008; 105(6):2064-9. PMC: 2538881. DOI: 10.1073/pnas.0711795105. View

Thorne N, Inglese J, Auld D . Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chem Biol. 2010; 17(6):646-57. PMC: 2925662. DOI: 10.1016/j.chembiol.2010.05.012. View

Sermet-Gaudelus I, De Boeck K, Casimir G, Vermeulen F, Leal T, Mogenet A . Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med. 2010; 182(10):1262-72. DOI: 10.1164/rccm.201001-0137OC. View

10.

Koopmann T, Verkerk A, Bezzina C, de Bakker J, Wilde A . The chemical compound PTC124 does not affect cellular electrophysiology of cardiac ventricular myocytes. Cardiovasc Drugs Ther. 2011; 26(1):41-5. DOI: 10.1007/s10557-011-6352-2. View

11.

Welch E, Barton E, Zhuo J, Tomizawa Y, Friesen W, Trifillis P . PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007; 447(7140):87-91. DOI: 10.1038/nature05756. View

12.

Peltz S, Welch E, Jacobson A, Trotta C, Naryshkin N, Sweeney H . Nonsense suppression activity of PTC124 (ataluren). Proc Natl Acad Sci U S A. 2009; 106(25):E64. PMC: 2700894. DOI: 10.1073/pnas.0901936106. View

13.

Harmer S, Mohal J, Kemp D, Tinker A . Readthrough of long-QT syndrome type 1 nonsense mutations rescues function but alters the biophysical properties of the channel. Biochem J. 2012; 443(3):635-42. DOI: 10.1042/BJ20111912. View

14.

Tan L, Narayan S, Chen J, Ditewig Meyers G, Bennett M . PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation. J Inherit Metab Dis. 2011; 34(2):443-7. DOI: 10.1007/s10545-010-9265-5. View

15.

Goldmann T, Overlack N, Wolfrum U, Nagel-Wolfrum K . PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C. Hum Gene Ther. 2011; 22(5):537-47. DOI: 10.1089/hum.2010.067. View

16.

Nicholson P, Muhlemann O . Cutting the nonsense: the degradation of PTC-containing mRNAs. Biochem Soc Trans. 2010; 38(6):1615-20. DOI: 10.1042/BST0381615. View

17.

Kopelowitz J, Hampe C, Goldman R, Reches M, Engelberg-Kulka H . Influence of codon context on UGA suppression and readthrough. J Mol Biol. 1992; 225(2):261-9. DOI: 10.1016/0022-2836(92)90920-f. View

18.

van den Akker P, Jonkman M, Rengaw T, Bruckner-Tuderman L, Has C, Bauer J . The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations. Hum Mutat. 2011; 32(10):1100-7. DOI: 10.1002/humu.21551. View

19.

Kellermayer R . Translational readthrough induction of pathogenic nonsense mutations. Eur J Med Genet. 2006; 49(6):445-50. DOI: 10.1016/j.ejmg.2006.04.003. View

20.

Auld D, Thorne N, Maguire W, Inglese J . Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci U S A. 2009; 106(9):3585-90. PMC: 2638738. DOI: 10.1073/pnas.0813345106. View